The overall effect size on eGFR was relatively modest in both studies, suggesting that firstly patients were required to be on the drug for long periods of time to gain the most benefit and secondly that there may be significant variance in response rates to tolvaptan.
← all excerpts
Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan.
1
—
—